Señales en vivo de AKBA | Maximiza tus Ganancias con Getagraph.com

COMPRAR 123016 min ago

@ $1.540

Emitido: 14 feb 2024 @ 11:12

Retorno: -13.64%

Señal anterior: feb 14 - 09:30

Señal anterior: Vender

Retorno: -1.28 %

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases...

Stats
Volumen de hoy	8.16M
Volumen promedio	5.10M
Capitalización de mercado	278.76M
EPS	$0 ( 2024-03-14 )
Próxima fecha de ganancias	( $-0.0900 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.75
ATR14	$0.00600 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-25	Burke Steven Keith	Sell	27 000	Common Stock
2024-02-29	Dahan Michel	Sell	8 661	Common Stock
2024-02-29	Hadas Nicole R.	Sell	5 974	Common Stock
2024-02-29	Butler John P.	Sell	46 570	Common Stock
2024-02-29	Burke Steven Keith	Sell	7 169	Common Stock

INSIDER POWER
87.13
Last 97 transactions
Buy: 11 050 463 \| Sell: 763 876

Volumen Correlación

Largo: 0.41 (neutral)

Corto: 0.72 (moderate)

Signal:(23.36) Neutral

Akebia Therapeutics Inc Correlación

10 Correlaciones Más Positivas
BNIXU	0.912
AMRB	0.905
NIU	0.904
COFS	0.903
WMG	0.902
APWC	0.895
PFG	0.891
QNRX	0.89
ADPT	0.888
CARE	0.886

10 Correlaciones Más Negativas
RMRM	-0.898
LNSR	-0.863
DWSH	-0.863
GOODM	-0.856
HAPP	-0.849
XLRN	-0.848
GXII	-0.847
PLMR	-0.846
RCMT	-0.846
LHDX	-0.844

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Akebia Therapeutics Inc Correlación - Moneda/Commodity

0.63
( weak )

-0.41
( neutral )

0.00
( neutral )

-0.51
( weak negative )

Akebia Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$194.62M
Beneficio Bruto:	$118.89M (61.09 %)
EPS:	$-0.280

FY	2023
Ingresos:	$194.62M
Beneficio Bruto:	$118.89M (61.09 %)
EPS:	$-0.280

FY	2022
Ingresos:	$292.60M
Beneficio Bruto:	$207.81M (71.02 %)
EPS:	$-0.580

FY	2021
Ingresos:	$213.58M
Beneficio Bruto:	$60.18M (28.18 %)
EPS:	$-1.700

Financial Reports:

No articles found.

Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Actualizaciones en tiempo real para Akebia Therapeutics Inc [AKBA]

Upcoming Earnings Alert